Canopy Growth is Back in the Marijuana Sector… What to Know Before You Buy

Canadian pot producer Canopy Growth (CGC) has a market value above $9 billion, helped by a huge investment from Corona parent Constellation Brands (STZ) and control over a big chunk of Canada's recreational weed market. It has struck up partnerships with celebrities and found new ways to enter the U.S. market. But after the departure of CEO Bruce Linton, who helped engineer many of those gains, is Canopy Growth stock a buy right now?

Canopy Growth Fundamental Analysis: Still No Profits

Canaccord analyst Matt Bottomley said in a report last month that Canopy Growth had “by far the #1 position in the Canadian market.” Some analysts this year have estimated that its recreational market share stands at around 30%. Stifel analyst W. Andrew Carter in June called Canopy Growth stock “the best investable opportunity” in the industry, saying the pot company was ahead of rivals in building out infrastructure to serve Canada's legal market.

Read the full article at Investor's Business Daily.

Don’t Stop Here

More To Explore

Market Brief: AI Risks and Fed Minutes Incoming

Market Snapshot Market Pulse: U.S. stocks edged sideways, buoyed by fresh AI chatter that kept tech afloat while industrial sectors shrugged off supply-chain jitters. Bond

AARD: 56% Drop Sparks Urgent Investor Scrutiny!

Overview: Aardvark Therapeutics, Inc. (Nasdaq: AARD) is a clinical-stage biotech focused on therapies for metabolic diseases and Prader-Willi Syndrome (PWS) – a rare genetic disorder

Gene-Editing Goldrush Meets AI and ETF Plays

Opening Recap Market Pulse: Gene-editing fervor rippled through biotech circles after a Mordor Intelligence report flagged double-digit growth in cell line development through 2031. Down